Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recent studies have identified new melanoma antigens that are recognised by CD4(+) T cells. Analysis of tumour-specific CD4(+) T-cell responses may lead to the development of optimal anti-cancer vaccines that can induce an orchestrated effort of tumour-specific CD4(+) and CD8(+) T cells in the fight against cancer.

Original publication

DOI

10.1016/s0960-9822(99)80442-4

Type

Journal article

Journal

Current biology : CB

Publication Date

09/1999

Volume

9

Pages

R695 - R697

Addresses

Institute of Molecular Medicine Nuffield Department of Medicine Oxford, OX3 9DS, UK. vcerundo@worf.molbiol.ox.ac.uk

Keywords

CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Animals, Mice, Neoplasms, Melanoma, Neoplasms, Experimental, Cancer Vaccines, Antigens, Neoplasm, Histocompatibility Antigens Class II, Antigen Presentation, Immunologic Surveillance, Models, Immunological